-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ox-01 in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ox-01 in Acute Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ox-01 in Acute Ischemic Stroke Drug Details: Ox-01 (uric acid) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OXE-103 in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OXE-103 in Traumatic Brain Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OXE-103 in Traumatic Brain Injury Drug Details: OXE-103 (SUN11031) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OX-40 Agonist Mab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OX-40 Agonist Mab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OX-40 Agonist Mab in Solid Tumor Drug Details: Monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DPV-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DPV-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DPV-001 in Non-Small Cell Lung Cancer Drug Details: DPV-001 (DRibble...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986178 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986178 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986178 in B-Cell Non-Hodgkin Lymphoma Drug Details: BMS-986178 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986178 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986178 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986178 in Solid Tumor Drug Details: BMS-986178 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tovorafenib in Craniopharyngioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tovorafenib in Craniopharyngioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tovorafenib in Craniopharyngioma Drug Details: Tovorafenib (TAK-580 (MLN2480)) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QBS-10072S in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. QBS-10072S in Gastric Cancer Drug Details: QBS-10072S is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nalmefene in Acute Opioid Overdosage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nalmefene in Acute Opioid Overdosage report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nalmefene in Acute Opioid Overdosage Drug Details: Nalmefene (OX-125) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vipoglanstat in Raynauds Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vipoglanstat in Raynauds Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Vipoglanstat in Raynauds DiseaseDrug Details:vipoglanstat (GS-248, OX-MPI) is under development for the treatment...